{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:18Z","timestamp":1788262158984,"version":"build-2803163510"},"reference-count":42,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The chronic nature of chronic myeloid leukemia (CML) has a negative impact on patients\u2019 health\u2010related quality of life (HRQOL) and the need for prolonged oral tyrosine kinase inhibitors (TKIs) poses a risk to low or nonadherence over time. This systematic review seeks to analyze HRQOL outcomes and adherence to TKIs among pediatric, adolescent, and young adult (AYA) patients with CML. Full\u2010text screening ultimately led to the inclusion of 12 articles focused on HRQOL, patient\u2010reported outcomes (PRO) and medication adherence.<\/jats:p><jats:p>There was heterogeneity in the findings among the included studies, especially in HRQOL and PROs. TKIs adherence ranged from 45%\u201378% using self\u2010report and 58%\u2013100% using medical and pharmacy records. Increased TKI adherence was significantly associated with better clinical outcomes, including overall survival. Our findings could inform efforts to develop behavioral interventions to optimize TKI adherence and improve HRQOL outcomes among AYA patients with CML.<\/jats:p>","DOI":"10.1002\/pbc.31686","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T16:11:04Z","timestamp":1743351064000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality of Life and Adherence to Tyrosine Kinase Inhibitors Among Pediatric, Adolescent, and Young Adult Chronic Myeloid Leukemia Patients: A Systematic Review"],"prefix":"10.1002","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-0818","authenticated-orcid":false,"given":"Rachel S.","family":"Werk","sequence":"first","affiliation":[{"name":"Division of Hematology Oncology and Stem Cell Transplantation, Ann &amp; Robert H. Lurie Children's Hospital of Chicago  Chicago Illinois USA"},{"name":"Department of Pediatrics Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey J.","family":"Mehrhoff","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology Primary Children's Hospital  Salt Lake City Utah USA"},{"name":"Department of Pediatrics University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-265X","authenticated-orcid":false,"given":"Sherif M.","family":"Badawy","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology and Stem Cell Transplantation, Ann &amp; Robert H. Lurie Children's Hospital of Chicago  Chicago Illinois USA"},{"name":"Department of Pediatrics Northwestern University Feinberg School of Medicine  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yapd.2023.04.002"},{"key":"e_1_2_9_3_1","volume-title":"Chronic Myeloid Leukemia (CML): Cancer Stat Facts","author":"E. Surveillance and E. R. Program","year":"2024"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.342.342"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00897"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010022\u201000673\u20105"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29699"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/11.2.103"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213557"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22019"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-015-2007-9"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2021.158"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.10.1140"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036498"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.02.040"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.560310"},{"issue":"17","key":"e_1_2_9_19_1","first-page":"4554","article-title":"Health\u2010Related Quality of Life in Chronic Myeloid Leukemia Patients Receiving Long\u2010Term Therapy With Imatinib Compared With the General Population. Blood","volume":"118","author":"Efficace F.","year":"2011","journal-title":"The Journal"},{"issue":"02","key":"e_1_2_9_20_1","first-page":"165","article-title":"Symptom Burden and Quality of Life Issues Among Patients of Chronic Myeloid Leukemia on Long\u2010Term Imatinib Therapy","volume":"38","author":"Unnikrishnan R.","year":"2017","journal-title":"Indian Journal of Medical and Paediatric Oncology"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2353-2"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256804"},{"key":"e_1_2_9_23_1","volume-title":"Manual of the Functional Assessment of Chronic Illness Therapy (FACIT\u2010scales), Version 4","author":"Cella D. F.","year":"1997"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:QURE.0000015297.91158.01"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433915"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200012150-00008"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4765.4765"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2012.121"},{"key":"e_1_2_9_29_1","volume-title":"The Medication Adherence Report Scale","author":"Horne R.","year":"2004"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-08585-w"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.766164"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325957414557263"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.06.263"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G163"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.9.1138"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1769-2"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-016-0919-1"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2013.01.017"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.06.040"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2044509"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010056"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3173"},{"issue":"5","key":"e_1_2_9_43_1","first-page":"611","article-title":"NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia","volume":"17","author":"Shah N. P.","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.31686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:28:42Z","timestamp":1745404122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.31686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/pbc.31686"],"URL":"https:\/\/doi.org\/10.1002\/pbc.31686","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"2024-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e31686"}}